Refeyn celebrates 500th installation
13 May 2025
Mass photometry technology pioneer Refeyn says it has installed its 500th system based on its novel single-particle bioanalytical technology.
This followed the Ploug Group at the University of Copenhagen Biotech Research & Innovation Centre’s receipt of two new mass photometer and MassFluidix HC systems to study proteins involved in disease-relevant pathways.
The Ploug Group uses mass photometry to study intravascular lipid metabolism, already citing it in a new research article investigating the regulation of lipoprotein lipase (LPL).
“We anticipate that the acquisition of mass photometry in our laboratory is going to be a game changer in our studies on purified proteins involved in intravascular lipolysis,” said group leader Dr. Michael Ploug.
Launched as a spin-out from Oxford University in 2018, Refeyn’s technology is now used in more than 30 countries, with mass photometry cited in more than 1,000 publications. Mass photometers are used by biopharma companies, CDMOs and CROs for scientific discovery, drug development and manufacturing.
